Skip to main content Accessibility help
×
Home

Effect of Fluctuating Extreme Temperatures on Tranexamic Acid

  • Carly Loner (a1), Michael Estephan (a2), Hillary Davis (a1), Jeremy T. Cushman (a1) (a3) and Nicole M. Acquisto (a1) (a4)...

Abstract

Introduction:

Tranexamic acid (TXA) is an antifibrinolytic agent shown to reduce morbidity and mortality in hemorrhagic shock. It has potential use in prehospital and wilderness medicine; however, in these environments, TXA is likely to be exposed to fluctuating and extreme temperatures. If TXA degrades under these conditions, this may reduce antifibrinolytic effects.

Problem:

This study sought to determine if repetitive temperature derangement causes degradation of TXA.

Methods:

Experimental samples underwent either seven days of freeze/thaw or heating cycles and then were analyzed via mass spectrometry for degradation of TXA. An internal standard was used for comparison between experimental samples and controls. These samples were compared to room temperature controls to determine if fluctuating extreme temperatures cause degradation of TXA.

Results:

The coefficient of variability of ratios of TXA to internal standard within each group (room temperature, freeze, and heated) was less than five percent. An independent t-test was performed on freeze/thaw versus control samples (t = 2.77; P = .17) and heated versus control samples (t = 2.77; P = .722) demonstrating no difference between the groups.

Conclusion:

These results suggest that TXA remains stable despite repeated exposure to extreme temperatures and does not significantly degrade. These findings support the stability of TXA and its use in extreme environments.

Copyright

Corresponding author

Correspondence: Carly Loner, MD Department of Emergency Medicine University of Rochester Medical Center 601 Elmwood Avenue, Box 655 Rochester, New York 14642 USA E-mail: Carly_loner@urmc.rochester.edu

References

Hide All
1. Blackbourne, LH, Czarnik, J, Mabry, R, et al. Decreasing killed in action and died of wounds rates in combat wounded. J Trauma. 2010;69(1):S14.
2. Evans, JA, Van Wessem, KJ, McDougall, D, Lee, KA, Lyons, T, Balogh, ZJ. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surgery. 2010;34(1):158163.
3. Mannucci, PM, Levi, M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356(22):23012311.10.1056/NEJMra067742
4. Nishida, T, Kinoshita, T, Yamakawa, K. Tranexamic acid and trauma-induced coagulopathy. J Intensive Care. 2017;5:5.
5. Shakur, H, Roberts, I, Bautista, R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):2332.
6. Morrison, JJ, Dubose, JJ, Rasmussen, TE, Midwinter, MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113119.
7. De Guzman, R, Polykratis, IA, Sondeen, JL, Darlington, DN, Cap, AP, Dubick, MA. Stability of tranexamic acid after 12-week storage at temperatures from -20 degrees C to 50 degrees C. Prehosp Emerg Care. 2013;17(3):394400.
8. WHO Model List of Essential Medications. 20th List (March 2017, Amended August 2017). http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1. Accessed September 10, 2018.
9. Gayet-Ageron, A, Prieto-Merino, D, Ker, K, Shakur, H, Ageron, FX, Roberts, I. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;391(10116):125132.
10. Armenian, P, Campagne, D, Stroh, G, et al. Hot and cold drugs: national park service medication stability at the extremes of temperature. Prehosp Emerg Care. 2017;21(3):378385.
11. Brown, LH, Krumperman, K, Fullager, CJ. Out-of-hospital medication storage temperatures: a review of the literature and directions for the future. Prehosp Emerg Care. 2004;8(2):200206.
12. Szucs, P, Allegra, JR, Fields, LA, et al. Storage temperatures of medications on an air medical helicopter. Air Med J. 2000;19(1):1921.
13. Allegra, JR, Brennan, J, Lanier, V, Lavery, R, MacKenzie, B. Storage temperatures of out-of-hospital medications. Acad Emerg Med. 1999;6(11):10981103.10.1111/j.1553-2712.1999.tb00110.x
14. Brown, LH, Bailey, LC, Medwick, T, Okeke, CC, Krumperman, K, Tran, CD. Medication storage temperatures on U.S. ambulances: a prospective multicenter observational study. Pharmopeial Forum. 2003;29(2):540544.
15. Church, WH, Hu, SS, Henry, AJ. Thermal degradation of injectable epinephrine. Am J Emerg Med. 1994;12(3):306309.
16. Valenzuela, TD, Criss, EA, Hammargren, WM, et al. Thermal stability of prehospital medications. Ann Emerg Med. 1989;18(2):173176.
17. Beasley, H, Ng, P, Wheeler, A, Smith, WR, Mcintosh, SE. The impact of freeze-thaw cycles on epinephrine. Wild Environ Med. 2015;26(4):514519.10.1016/j.wem.2015.04.001
18. Tranexamic Acid Injection. United States Pharmacopeia-National Formulary. https://www.usp.org/. Accessed August 2018.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed